Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments

1 Apr 2022

Abstract excerpt

Abstract: TP53 is a key tumor suppressor gene that plays an important role in regulating apoptosis, senescence, and DNA damage repair in response to cellular stress. Although somewhat rare, TP53 -mutated AML has been identified as an important molecular subgroup with a prognosis that is arguably the worst of any. Survival beyond one year is rare after induction chemotherapy with or without consolidative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer-related Molecular Pathways
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35479302
DOI: 10.2147/ott.s265637

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical DevelopmentsPMID 35479302Read ↗

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read ↗

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.Semantic proximity Read ↗

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Semantic proximity Read ↗

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read ↗

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxSemantic proximity Read ↗

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.Semantic proximity Read ↗

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?Semantic proximity Read ↗

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.Semantic proximity Read ↗

Evaluating targeted therapies in older patients with TP53-mutated AML.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.Semantic proximity Read ↗

Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.